SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*
上海君實生物醫藥科技股份有限公司
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 1877)

VOLUNTARY ANNOUNCEMENT – THE PHASE III CLINICAL STUDY OF ANTI-IL-17A MONOCLONAL ANTIBODY FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS PATIENTS MET PRIMARY ENDPOINTS

This announcement is made by Shanghai Junshi Biosciences Co., Ltd.* (上海君實生物醫藥科技股份有限公司) (the "**Company**") on a voluntary basis. Reference is also made to the overseas regulatory announcement of the Company dated 7 September 2025.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that the Company's product, recombinant humanized anti-IL-17A monoclonal antibody (code: JS005) has achieved positive results in a multi-center, randomized, double-blind, parallel, placebo-controlled pivotal registrational clinical study (study number: JS005-005-III-PsO) for the treatment of moderate to severe plaque psoriasis. Both the co-primary endpoints and key secondary endpoints showed statistically significant and clinically meaningful improvements. The Company plans to submit the new drug application of this product to the regulatory authorities in the near future.

ABOUT JS005

JS005 is an anti-IL-17A monoclonal antibody independently developed by the Company. IL (interleukin)-17A is a pleiotropic cytokine, and the disordered secretion of which is closely related to the occurrence and progression of autoimmune diseases such as psoriasis, rheumatoid arthritis and ankylosing spondylitis. By binding to IL-17A with high affinity and selectively blocking the binding of IL-17A with its receptor IL-17RA/IL-17RC, JS005 blocks the activation of downstream signaling pathways and the release of inflammatory factors, thereby effectively alleviating the symptoms of autoimmune diseases. As at the date of this announcement, the phase III clinical study of JS005 for the treatment of moderate to severe plaque psoriasis has met the co-primary endpoints and key secondary endpoints. All subjects in the phase II clinical study of JS005 for the treatment of active ankylosing spondylitis have completed the primary endpoint visit and entered the extension treatment period.

ABOUT JS005-005-III-PsO

Psoriasis is a common chronic, recurrent, inflammatory, and systemic disease mediated by the immune system. Its prevalence varies significantly across different regions: the overall global prevalence of psoriasis ranges from 2.0% to 3.0%, while in China it is 0.47%. According to data released by the World Psoriasis Day Consortium, the total number of patients with psoriasis worldwide is approximately 125 million, and shows a year-on-year increasing trend. Psoriasis can be accompanied by other systemic abnormalities, patients with moderate-to-severe psoriasis have an increased risk of developing metabolic syndrome and atherosclerotic cardiovascular disease. Mental health conditions such as depression, anxiety, and suicidal tendencies caused by physical and psychological distress are also relatively common among the patients with psoriasis. Therefore, psoriasis is a disease that seriously affects the physical and mental health of patients, and is also a global disease that urgently needs to be addressed.

As at the date of this announcement, the multi-center, randomized, double-blind, parallel, placebo-controlled pivotal registrational study (study number: JS005-005-III-PsO) of JS005 has been successfully completed and met the co-primary endpoints and key secondary endpoints. Led by Professor Zhang Jianzhong* (張建中) from the Peking University People's Hospital* (北京大學人民醫院), the study was conducted in 60 clinical sites across China, and its primary objective is to determine whether the proportion of participants achieving at least a 90% improvement in Psoriasis Area and Severity Index (PASI 90) and a static Physician Global Assessment (the **"sPGA**") score of 0 or 1 at week 12 in JS005 group are both superior to that of the placebo group.

The study results showed that, compared to the placebo, JS005 significantly improved the area and severity of psoriasis lesion in participants, and the proportion of participants achieving a sPGA score of 0 or 1 was also significantly higher, and JS005 demonstrated good safety in participants with moderate to severe plaque psoriasis. The relevant study results will be announced at future international academic conferences.

RISK WARNING

Due to the high-tech, high-risk, and high value-added characteristics of pharmaceutical products, there are significant risks and uncertainties in the research, development, and commercialization processes of drugs. These multiple stages are susceptible to various uncertain factors. Investors are advised to make cautious decisions and pay careful attention to investment risks. The Company will actively pursue the described project and fulfill its information disclosure obligations in a timely manner for subsequent progress in strict compliance with relevant regulations.

By order of the Board
Shanghai Junshi Biosciences Co., Ltd.*
Mr. Xiong Jun
Chairman

Shanghai, the PRC, 7 September 2025

As at the date of this announcement, the Board of Directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Zou Jianjun, Mr. Li Cong, Mr. Zhang Zhuobing, Dr. Yao Sheng, Dr. Wang Gang and Dr. Li Xin as executive Directors; Mr. Tang Yi as a non-executive Director; and Mr. Zhang Chun, Dr. Feng Xiaoyuan, Dr. Yang Yue, Mr. Li Zhongxian and Ms. Lu Kun as independent non-executive Directors.

* *For identification purpose only*